See more : WILLPLUS Holdings Corporation (3538.T) Income Statement Analysis – Financial Results
Complete financial analysis of Senti Biosciences, Inc. (SNTI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senti Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Orora Limited (ORRAF) Income Statement Analysis – Financial Results
- American Outdoor Brands, Inc. (AOUT) Income Statement Analysis – Financial Results
- Deere & Company (DE) Income Statement Analysis – Financial Results
- International Money Express, Inc. (IMXI) Income Statement Analysis – Financial Results
- Kala Pharmaceuticals, Inc. (0JQ2.L) Income Statement Analysis – Financial Results
Senti Biosciences, Inc. (SNTI)
About Senti Biosciences, Inc.
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.56M | 4.29M | 2.29M | 394.00K | 85.00K |
| Cost of Revenue | 5.24M | 3.92M | 3.01M | 15.96M | 14.52M |
| Gross Profit | -2.68M | 366.00K | -719.00K | -15.56M | -14.44M |
| Gross Profit Ratio | -104.76% | 8.54% | -31.38% | -3,949.75% | -16,987.06% |
| Research & Development | 32.15M | 34.07M | 21.96M | 15.96M | 14.52M |
| General & Administrative | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.87M | 40.85M | 21.25M | 9.30M | 7.34M |
| Other Expenses | 27.69M | 12.42M | -470.00K | -172.00K | 0.00 |
| Operating Expenses | 95.29M | 74.92M | 42.74M | 25.09M | 7.39M |
| Cost & Expenses | 94.71M | 74.92M | 42.74M | 25.09M | 21.92M |
| Interest Income | 2.86M | 1.70M | 11.00K | 88.00K | 674.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.43M | 3.89M | 3.01M | 1.99M | 427.00K |
| EBITDA | -61.34M | -70.63M | -39.68M | -22.71M | -21.36M |
| EBITDA Ratio | -2,395.00% | -1,647.90% | -1,633.09% | -5,703.30% | -25,123.53% |
| Operating Income | -92.73M | -70.63M | -40.45M | -24.69M | -21.78M |
| Operating Income Ratio | -3,620.73% | -1,647.90% | -1,765.43% | -6,267.51% | -25,625.88% |
| Total Other Income/Expenses | 9.32M | 12.42M | -14.87M | 4.83M | 625.00K |
| Income Before Tax | -83.41M | -58.21M | -55.32M | -19.86M | -21.16M |
| Income Before Tax Ratio | -3,256.77% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| Income Tax Expense | 0.00 | -12.42M | 11.00K | 150.00K | 0.00 |
| Net Income | -92.92M | -58.21M | -55.32M | -19.86M | -21.16M |
| Net Income Ratio | -3,628.23% | -1,358.14% | -2,414.62% | -5,041.12% | -24,890.59% |
| EPS | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| EPS Diluted | -16.01 | -22.29 | -12.67 | -4.55 | -1.56 |
| Weighted Avg Shares Out | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
| Weighted Avg Shares Out (Dil) | 4.44M | 2.61M | 4.37M | 4.37M | 13.59M |
Senesco Completes Acquisition of Fabrus
Senesco Technologies Reports Second Quarter of Fiscal Year 2014 Financial Results
Senesco Announces Presentation on the Effectiveness of eIF5A in Inhibiting Tumor Progression in Liver Cancer Models
Senesco Opens Two New Clinical Trial Sites and Initiates Treatment of the First Patient in South Africa
Senesco Pays Off Line of Credit
In Non-clinical Cancer Studies Senesco’s Therapeutic Candidate, SNS01-T, Works Synergistically in Combination with the Active Components of Revlimid® and Velcade®
Senesco Technologies Reports Second Quarter of Fiscal Year 2014 Financial Results
First Patient in Cohort 4 Receives Infusion of Senesco’s Therapeutic Candidate, SNS01-T, For the Treatment of Multiple Myeloma and Non-Hodgkins Lymphoma in Phase 1b/2a Clinical Trial
Senesco to Present at Biotech Showcase™ 2014
Senesco Announces Letter of Intent to Merge with Fabrus
Source: https://incomestatements.info
Category: Stock Reports